about
Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic DrugsNew perspectives on exploitation of incretin peptides for the treatment of diabetes and related disordersIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsObesity and cancer: at the crossroads of cellular metabolism and proliferationGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesSphingosine kinase 1 isoform-specific interactions in breast cancerIndirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus.Optical control of insulin release using a photoswitchable sulfonylureaPathophysiology after pancreaticoduodenectomy.Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetesIncretins: their physiology and application in the treatment of diabetes mellitus.Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Albiglutide: a review of its use in patients with type 2 diabetes mellitus.An updated review on cancer risk associated with incretin mimetics and enhancers.Safety of antidiabetes medications: An update.Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones.Adverse Effects Associated With Newer Diabetes Therapies.Melatonin, mitochondria, and the metabolic syndrome.Exenatide: pharmacokinetics, clinical use, and future directions.Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.Chronomedicine and type 2 diabetes: shining some light on melatonin.Glucoregulatory, endocrine and morphological effects of [P5K]hymenochirin-1B in mice with diet-induced glucose intolerance and insulin resistance.Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.Activation of GLP-1 and gastrin signalling induces in vivo reprogramming of pancreatic exocrine cells into beta cells in mice.Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease.Acute pancreatitis during GLP-1 receptor agonist treatment. A case report.The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
P2860
Q26750845-7B3887ED-0AF2-4BEF-B3E6-3EF590E00F59Q26777654-7EEB0643-941E-4C4C-9C19-8F0E8C2A2D30Q26778608-BCD7F8ED-9847-4BFC-9616-9C82AAAAB984Q27003989-3E64798F-E7BC-484D-915F-9BD96F7AF4ABQ28067465-07F1B580-742C-4F44-8922-C72C6F45D401Q33631908-99997D1C-7621-4C70-9082-62A5489206EEQ34368524-014C8059-5849-46A4-9CA3-C4B9A7C55563Q34397447-37AEBA20-EE70-4264-B8DC-440411C00FECQ35625352-CB8B9716-4AA5-4132-9138-4DB8E0D3C35AQ35784245-EC7B56AE-0884-4132-8864-CE1671149B18Q37340223-4D7EDE72-4425-4796-8C38-D7008D3876F1Q37501257-8CBA8234-0CF5-4279-AFAD-0F1E46774CC0Q37509313-403C2204-9EB9-485C-9532-26D1252C9B1DQ38188871-16E93BDC-4EC3-4BEC-930C-2F406C2C16DFQ38225693-3F90B007-203B-4EB7-9E89-79F32397D113Q38264842-21147EDF-1308-4AAC-AB22-06467F11916FQ38286444-0ED61722-CDBA-4E3E-91EB-DB8E14BBE469Q38380559-30D3A814-CA8F-4CD3-A034-6B1CBEC55397Q38388920-B5F9609A-95FD-478F-8343-E50166FD9792Q38395221-7DCED746-05DF-4565-91B3-35C8AE0CB253Q38514840-C2F08E18-6420-4153-A000-850D82776CDDQ38546214-80B2B26E-B980-4F5D-BA1D-FE4D206770B9Q38618827-6934BE0D-B7C5-4B54-8028-B8459CB6BAF6Q38770746-73286098-149C-4685-88D5-DEF8A3AEB420Q38815498-CF28D8F6-7D0D-45FB-9820-40AEF183F6C7Q39040818-4C472FE9-CF92-4F6B-8236-ECCB5D8B3CC6Q39859162-6B627618-1C11-497C-9CF8-DF2A4E64ABACQ41784210-2842A54B-D620-4918-9906-795DCFECC476Q45778975-F07CA7F9-4E72-407B-B4A9-945352260E17Q45783993-9B52C328-3AFA-4C1E-9FA3-8CFC26E931AFQ45951109-EC185B0E-C37A-40B0-82A8-E9FC6A277EB4Q46185294-4E65E7FA-FC28-40CF-95E6-0FB17F5109D2Q47119201-80C87BBB-D882-45F9-AD29-49D18030D79BQ49202455-92C589FA-637A-4A2B-A9A2-AB7156199726Q51093729-F0199890-BA7F-4493-97EE-FD91AEC77472Q51320034-FF81B1E7-598D-4865-9ED1-4614B9E41AE0Q57816534-923509CB-68A8-4894-B994-CB38E5F45A51
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Do GLP-1-based therapies increase cancer risk?
@en
Do GLP-1-based therapies increase cancer risk?
@nl
type
label
Do GLP-1-based therapies increase cancer risk?
@en
Do GLP-1-based therapies increase cancer risk?
@nl
prefLabel
Do GLP-1-based therapies increase cancer risk?
@en
Do GLP-1-based therapies increase cancer risk?
@nl
P2860
P921
P356
P1433
P1476
Do GLP-1-based therapies increase cancer risk?
@en
P2093
Michael A Nauck
Nele Friedrich
P2860
P304
P356
10.2337/DCS13-2004
P407
P478
36 Suppl 2
P5008
P577
2013-08-01T00:00:00Z